Who
John L. Higgins
Director
Company insider
Files Form 4 as: Director, Bio-Techne; Director, OmniAb; Chief Executive Officer, Ligand Pharmaceuticals; Director, BioCryst Pharmaceuticals; EVP, Finance, Corp Dev. & CFO, Connetics.
In numbers
- Trades disclosed
- 387
- Buys
- 16
- Sells
- 45
- Bought
- $1.5M
- Sold
- $68.7M
- Companies
- 5
- Companies where not an officer
- 3
- First trade
- 3 Sep 2003
- Last trade
- 28 Sep 2026
- Last filed
- 30 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Sep 2026filed 30 Sep 2026 | TECH Bio-TechneLife-science tools | SEC FORM 4 Code M | —15,940 at $0.00 | filing |
| 28 Sep 2026filed 30 Sep 2026 | TECH Bio-TechneLife-science tools | SEC FORM 4 Code F | $403K5,562 at $72.51 | filing |
| 28 Sep 2026filed 30 Sep 2026 | TECH Bio-Techneoption or derivative · Life-science tools | SEC FORM 4 Code M | —15,940 at $0.00 | filing |
| 28 Sep 2026filed 30 Sep 2026 | TECH Bio-Techneoption or derivative · Life-science tools | SEC FORM 4 Code M | —15,940 at $0.00 | filing |
| 28 Sep 2026filed 30 Sep 2026 | TECH Bio-TechneLife-science tools | SEC FORM 4 Code M | —15,940 at $0.00 | filing |
| 28 Sep 2026filed 30 Sep 2026 | TECH Bio-TechneLife-science tools | SEC FORM 4 Code F | $403K5,562 at $72.51 | filing |
| 17 Jun 2026filed 18 Jun 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Code M | —20,000 | filing |
| 17 Jun 2026filed 18 Jun 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code M | —20,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Code M | —20,000 | filing |
| 30 Jan 2026filed 30 Jan 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Code M | —13,172 | filing |
| 30 Jan 2026filed 30 Jan 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code M | —13,172 at $0.00 | filing |
| 30 Jan 2026filed 30 Jan 2026 | OABI OmniAboption or derivative · Life-science tools | SEC FORM 4 Code M | —13,172 at $0.00 | filing |
| 30 Jan 2026filed 30 Jan 2026 | OABI OmniAbLife-science tools | SEC FORM 4 Code M | —13,172 | filing |
| 7 Nov 2025filed 10 Nov 2025 | OABI OmniAbLife-science tools | SEC FORM 4 Bought | $57K41,038 at $1.38 | filing |
| 6 Nov 2025filed 10 Nov 2025 | OABI OmniAbLife-science tools | SEC FORM 4 Bought | $51K36,223 at $1.41 | filing |
News
OmniAb (NASDAQ:OABI) Stock Price Target Raised at Leerink PartnersOABI · dailypolitical.com · 7 Oct 2026
0 headlines in the last 90 days name John L. Higgins; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.